Jess Jankowski - 24 Oct 2022 Form 4 Insider Report for NANOPHASE TECHNOLOGIES Corp (SLSN)

Role
President, CEO, Director
Signature
Jess A. Jankowski
Issuer symbol
SLSN
Transactions as of
24 Oct 2022
Net transactions value
-$7,747
Form type
4
Filing time
26 Oct 2022, 18:06:19 UTC
Previous filing
22 Jun 2022
Next filing
07 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NANX Common Stock Options Exercise $1,038 +2,500 +4.2% $0.4150 61,500 24 Oct 2022 Direct F1
transaction NANX Common Stock Sale $5,875 -2,500 -4.1% $2.35 59,000 24 Oct 2022 Direct
transaction NANX Common Stock Options Exercise $332 +800 +1.4% $0.4150 59,800 25 Oct 2022 Direct F1
transaction NANX Common Stock Sale $1,872 -800 -1.3% $2.34 59,000 25 Oct 2022 Direct
holding NANX Common Stock 1,000 24 Oct 2022 Spouse's IRA
holding NANX Common Stock 59,000 24 Oct 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NANX Common Stock (right to purchase) Options Exercise $1,038 -2,500 -2.8% $0.4150 87,500 24 Oct 2022 Common Stock 90,000 $0.4150 Direct F2
transaction NANX Common Stock (right to purchase) Options Exercise $332 -800 -0.91% $0.4150 86,700 25 Oct 2022 Common Stock 87,500 $0.4150 Direct F2
holding NANX Common Stock (right to purchase) 90,000 24 Oct 2022 Common Stock 90,000 $0.5200 Direct F3
holding NANX Common Stock (right to purchase) 81,000 24 Oct 2022 Common Stock 81,000 $0.4400 Direct F4
holding NANX Common Stock (right to purchase) 69,000 24 Oct 2022 Common Stock 69,000 $0.4200 Direct F4
holding NANX Common Stock (right to purchase) 81,000 24 Oct 2022 Common Stock 81,000 $0.6800 Direct F4
holding NANX Common Stock (right to purchase) 90,000 24 Oct 2022 Common Stock 90,000 $0.8200 Direct F5
holding NANX Common Stock (right to purchase) 16,500 24 Oct 2022 Common Stock 16,500 $0.5100 Direct F3
holding NANX Common Stock (right to purchase) 90,000 24 Oct 2022 Common Stock 90,000 $0.4500 Direct F3
holding NANX Common Stock (right to purchase) 90,000 24 Oct 2022 Common Stock 90,000 $4.17 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
F2 These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
F3 Subject to certain restrictions, beginning on this date, options vest in three equal installments.
F4 Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.
F5 Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

Remarks:

Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having shares from this grant sold, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. The maturity of these rights cannot be extended beyond the IRS statutory limit of ten years.